While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability.
Stephen TaubJanuary 19, 2023
Andrey Rudakov/Bloomberg
After a disastrous first half of the year, at least three biopharma hedge funds finished 2022 in the black, while another came close to being profitable. For most of these firms — which rarely make significant
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.